Veracyte, Inc. - Common Stock (NQ:VCYT)

45.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

July 20, 2022

From Veracyte, Inc.

Via Business Wire

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

July 14, 2022

From Veracyte, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Analyst Ratings for Veracyte ↗

May 04, 2022

Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:

Via Benzinga

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

July 13, 2022

From Veracyte, Inc.

Via Business Wire

Small Cap Biotechs Regain Momentum ↗

July 11, 2022

Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values.

Via Talk Markets

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

June 27, 2022

From Veracyte, Inc.

Via Business Wire

Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗

June 22, 2022

Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.

Via Talk Markets

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

June 20, 2022

From Veracyte, Inc.

Via Business Wire

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

June 03, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

May 31, 2022

From Veracyte, Inc.

Via Business Wire

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Present at Upcoming Investor Conferences

May 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

May 16, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Earnings Perspective: Return On Capital Employed ↗

May 13, 2022

Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million.

Via Benzinga

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

May 12, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting

May 12, 2022

From Veracyte

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

May 05, 2022

During Thursday, 351 stocks hit new 52-week lows.

Via Benzinga

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

May 04, 2022

From Veracyte, Inc.

Via Business Wire

Recap: Veracyte Q1 Earnings ↗

May 03, 2022

Veracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by...

Via Benzinga

Veracyte Announces First Quarter 2022 Financial Results

May 03, 2022

From Veracyte, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

Preview: Veracyte's Earnings ↗

May 02, 2022

Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will...

Via Benzinga

Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis

May 02, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference

April 28, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference

April 26, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022

April 19, 2022

From Veracyte, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.